Three drugs have been granted ‘rare paediatric disease designation’ (RPDD) in the US by the Food and Drug Administration (FDA). The FDA grants RPDD for serious or life-threatening diseases that affect fewer than 200,000 people in the United States and primarily affect patients less than 18 years of age. ETD001 ETD001 is a novel, first […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!